Overview

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

To evaluate the therapeutic equivalence of the lest formulation of Mometasone Furoate Nasal Spray, 50 mcg to the marketed formulation NASONEX® (mometasone furoate monohydrate) Nasal Spray, 50 mcg/actuation in patients with seasonal allergic rhinitis

Phase:

Phase 3

Details

Lead Sponsor:

Amneal Pharmaceuticals, LLC

Collaborator:

Novum Pharmaceutical Research Services

Treatments:

Mometasone Furoate